Heparin and heparan sulfates are closely related linear anionic polysaccharides, called glycosaminoglycans, which exhibit a number of important biological and pharmacological activities. These polysaccharides, having complex structures and polydispersity, are biosynthesized in the Golgi of animal cells. While heparan sulfate is a widely distributed membrane and extracellular glycosaminoglycan, heparin is found primarily intracellularly in the granules of mast cells. While heparin has historically received most of the scientific attention for its anticoagulant activity, interest has steadily grown in the multi-faceted role heparan sulfate plays in normal and pathophysiology. The chemical synthesis of these glycosaminoglycans is largely precluded by their structural complexity. Today, we depend on livestock animal tissues for the isolation and the annual commercial production of hundred ton quantities of heparin used in the manufacture of anticoagulant drugs and medical device coatings. The variability of animal-sourced heparin and heparan sulfates, their inherent impurities, the limited availability of source tissues, the poor control of these source materials and their manufacturing processes, suggest a need for new approaches for their production. Over the past decade there have been major efforts in the biotechnological production of these glycosaminoglycans, driven by both therapeutic applications and as probes to study their natural functions. This review focuses on the complex biology of these glycosaminoglycans in human health and disease, and the use of recombinant technology in the chemoenzymatic synthesis and metabolic engineering of heparin and heparan sulfates.
Introduction
Heparan sulfate (HS) and heparin (HP) are anionic, linear polysaccharides, called glycosaminoglycans (GAGs), which are abundant in all animal species. These GAGs are biosynthesized as proteoglycans (PGs), consisting of an elongated core protein and one or more GAG chains covalently attached to core protein serine residues [1] . The structurally related HS and heparin GAGs are composed of a repeating disaccharide unit, comprised of β-D-glucuronic acid (GlcA) or α-Liduronic acid (IdoA) 1, 4-glycososidically linked to D-glucosamine (GlcN) (Fig. 1A) . This disaccharide unit can be modified in various ways. The uronic acid residues can be modified with a 2-O-sulfo group (IdoA2S and rarely GlcA2S). The GlcN residue can contain an N-acetyl or N-sulfo group (GlcNAc or GlcNS), as well as modified with 6-Osulfo group and 3-O-sulfo groups (GlcNAc6S and GlcNS6S, or rarely GlcNAc3S and GlcNS3S or GlcNAc3S6S and GlcNS3S6S [2] ). With 32 (2 6 ) possible modifications for each disaccharide unit (although not all possible disaccharide units have been detected in natural HS/HP), the structures of HS and heparin are extremely complex and information dense. Heparin has a relatively uniform high level of sulfation (2.5-3 sulfo groups/disaccharide). In contrast, HS has an overall lower level of sulfation (0.5-1.5 sulfo groups/disaccharide) and a domain structure, which is determined by the presence or absence of GlcNS residues. Long stretches of GlcNAc-containing disaccharides correspond to the largely Fig. 2 . Biosynthesis of heparin/HS Synthesis begins with the stepwise addition of four monosaccharides (Xyl, Gal, Gal, and GlcA) to a serine residue of the core protein. Polymerization extends the chain by alternately adding GlcNAc and GlcA, and the chain is modified by epimerase and sulfotransferase enzymes to produce a variable structure, which includes high and low sulfated domains (NS and NA respectively) and antithrombin binding sites. unsulfated NA domain, while shorter clusters of GlcNS-containing disaccharides correspond to the more highly sulfated NS domains, which are rich in IdoA, IdoA2S and GlcNS6S residues [3, 4] . Heparin, a widely used anticoagulant drug, is essentially an extended NS domain with a very high level of sulfation, and rich in trisulfated disaccharides of the structure GlcNS6S-IdoA2S. The rare 3-sulfo group found in both heparin and HS is an essential component of the antithrombin III (AT) binding site, a pentasaccharide sequence that activates AT and which is responsible for anticoagulant activity [2] .
HS and heparin are biosynthesized in the endoplasmic reticulum (ER) and the Golgi compartments. Biosynthesis begins in the ER with the stepwise addition of four monosaccharides (Xyl-Gal-Gal-GlcA) to a serine residue in the core protein, which form the tetrasaccharide linker region (Fig. 2) [5] . Heparin is biosynthesized exclusively on the serglycin core, while HS is can be biosynthesized on a variety of different core proteins, including members of the syndecan and glypican families [6, 7] . Glycosyltransferase enzymes catalyze the alternating addition of UDPactivated GlcA and GlcNAc residues to polymerize the chain, which is then modified by N-deacetylase, C5-epimerase and sulfotransferase enzymes [5] . N-deacetylase/N-sulfotransferases (NDST) are bifunctional enzymes (multiple isoforms) that replace the N-acetyl group with an N-sulfo group, a critical step for formation of domain structures [3] . Subsequent modifications by C5-epimerase and O-sulfotransferases (OSTs) are dependent on the presence of GlcNS residues (NS domains), while NA domains remain largely unmodified [3, 8] . Iduronic acid residues are produced by C5-epimerase, which converts GlcA into IdoA, working in concert with 2-O-sulfotransferase (2OST) to give IdoA2S. In rare cases, 2OST modifies GlcA to form GlcA2S. GlcNS residues are then modified by 6-O-sulfotransferases (6OSTs), followed by 3-O-sulfotransferases (3OSTs). There are multiple isoforms of both 6OST and 3OST that display different specificity in their recognition sites. Tissue specific expression of different enzyme isoforms fine-tunes the synthesis of HP and HS to produce different structures, allowing adaptation of function to the local cellular environment. HS isolated from different tissues have different ratios of component disaccharides, which can be thought of as a kind of "glyco-fingerprint," and can show distinctive changes in certain cancers [9] [10] [11] .
Bioengineering of HP and HS will provide a source of molecules to investigate the structure-activity relationships of these important and ubiquitous biopolymers. Moreover, they may generate novel therapeutic strategies for the treatment of coagulation disorders, infectious disease, inflammatory conditions and cancers, and other pathologies in which these GAGs play a role.
Activities of HP/HS

Anticoagulation
The combinatorial complexity of HS structure and biosynthesis translates into an equally complex set of biological activities. The most wellknown and established pharmacological activity of the heparin GAG is its anticoagulant activity. Heparin has been widely used as an anticoagulant drug since the 1930s [2] , and today is an essential drug for treating thrombosis and related conditions. Interestingly, the biological function of endogenous heparin is not as an anticoagulant. Heparin is biosynthesized in mast cells and stored intracellularly and does not normally come into contact with blood. While the precise biological function of heparin is still unknown, it might be related to mast cell response to parasitic infections [2, 12] . The anticoagulant activity of heparin is mediated by its binding to antithrombin III (AT), an inhibitor of serine proteases, including thrombin and factor Xa, involved in the coagulation cascade (Fig. 3A) [2] . On binding heparin, AT undergoes a conformational change that amplifies its inhibitory activity by several orders of magnitude. The interaction between AT and heparin is mediated through a specific pentasaccharide sequence with a central 3-O-sulfo group, termed the AT-binding site (Fig. 1) . This binding site is also found in endothelial HS and may provide a basal level of anticoagulant activity responsible for the blood compatibility of the endothelium [13] . Interestingly, inhibition of thrombin (anti-FIIa activity) requires more than a pentasaccharide AT binding site, a chain of 16-18 saccharides is required for irreversible binding of thrombin by the HP-AT in a ternary complex. However, the AT pentasaccharide sequence bound to AT is only sufficient for the direct inhibition of factor Xa making it a specific anti-FXa agent. This discovery led to the development of low molecular weight heparins (LMWHs) as selective for factor Xa inhibitors (anti-FXa/anti-FIIa activity of~5-10), which was believed would reduce bleeding complications and heparininduced thrombocytopenia [13] [14] [15] .
Signaling and development
A much more complex biological activity of HS-GAGs is their role in developmental biology and cell signaling. Cell surface and extracellular matrix (ECM) HSPGs exhibit complex pleiotropic effects, playing roles in cell differentiation, migration, angiogenesis, and regulation of cell signaling [16] . HS is essential for proper development, and mutations in HS biosynthetic genes are known to cause a range of conditions resulting in abnormal bone and organ formation [17] . As a major component of the ECM, HSPGs exhibit binding affinities for major ECM proteins including fibronectin, collagen and laminin, which are critical in cell adhesion and provide spatial context for cell signaling [16, 18, 19] . With a diverse array of sub-structures, HS acts as a binding platform for a host of extracellular signaling molecules such as growth factors, chemokines and morphogens, regulating their diffusion and distribution in the ECM [16, 18, 19] . HS can also signal directly as a co-receptor, as in the case of fibroblast growth factor (FGF) signaling [20, 21] . The FGF family is responsible for directing a wide range of developmental processes. Formation of an FGF-FGF receptor (FGFR) signaling complex requires HS, whose role is to coordinate specific pairings of FGFs and FGFRs by binding to each, which have different preferences in HS structure [21, 22] . However, the precise nature and specificity of these interactions is still being investigated.
It is more difficult to say exactly how HSPGs modulate the response to other extracellular signaling molecules. In addition to FGFs, HS binds a number of other growth factors (GFs) (vascular endothelial (VE) GF, platelet derived GF, glial cell-derived neurotrophic factor, and hepatocyte GF) and cytokines (interleukin (IL)-12, midkine, pleiotrophin, platelet factor 4) [18, 19, 23] . How this binding affects the complex spatial biology of the ECM is poorly understood, especially given the diverse array of differentially expressed HSPGs, and the variable composition of their HS chains [20] . One mechanism by which HSPGs modulate signaling pathways is by stabilizing gradients of signaling molecules, which provide spatial information to cells during development [24] . In angiogenesis, HSPGs establish a gradient of VEGF, which provides spatial context for the migrating endothelial cells which will form the blood vessel ( Fig. 3D ) [25] . HSPGs can also facilitate the internalization of signaling molecules or act as storage, to be released by heparanase, a mammalian endoglucuronidase that cleaves HS chains [23, 26, 27] . In wound healing, heparanase accelerates repair through the release of these bound signaling molecules [28] . Moreover, increased syndecan expression is seen in migrating and proliferating cells at the injury site, which likely act to regulate ECM organization and growth factor response [29, 30] .
Infectious disease, inflammation, and cancer
HSPGs are a very common cellular receptor for viral and bacterial pathogens, which bind the HS chain to facilitate attachment and invasion of specific host tissues (Fig. 3B ) [12] . Papillomavirus infection requires binding to either syndecan or glypican HS, and ectopic expression of these HSPGs has been shown to enhance infectivity [31] . Some viruses recognize specific sequences in HS, as seen in herpes simplex virus type-1, whose glycoprotein D binds a 3-O-sulfo group containing octasaccharide to trigger fusion of the host cell and virus [32] . Many intracellular bacterial pathogens such as those in the genus Chlamydia and Borrelia burgdorferi, the causative agent of Lyme disease, invade host cells through similar mechanisms. The malarial protozoan Plasmodium falciparum infects liver tissue by binding to hepatocyte-associated HS chains, allowing remarkable specificity in host cell infection [33] . HSPGs can also play a key role in the virulence of many bacterial infections. Helicobacter pylori and Pseudomonas aeruginosa stimulate the shedding of syndecan-1, which can inhibit neutrophil-mediated bacterial killing, and exacerbate inflammatory damage to tissues [34, 35] .
HSPGs are intimately involved in inflammatory processes, primarily for their role in regulating leukocyte extravasation (Fig. 3C) . Leukocytes in the blood first weakly bind to the endothelial surface and roll along it, caused by the interaction between endothelial HS and L-selectin and Pselectins on the leukocyte [36, 37] . Interleukins and chemokines bound to endothelial HS attract the leukocyte to the site of injury [16] , where it activates integrins to produce a stronger adhesion in preparation for extravasation. HSPGs are major structural components of basement membranes, along with laminin and collagen, and provide a physical barrier to invading cells. Leukocytes extravasating to injury sites break down this barrier through the action of heparanase and various proteases, releasing biologically active HS fragments and their bound signaling molecules in the process [36] . Heparanase expression in many cancers can correlate with poor prognosis and higher metastatic potential as a result of co-opting this extravasation mechanism [38, 39] . Remarkably, metastatic potential can be acquired by non-metastatic Tlymphoma cells on transfection with heparanase [40] . The breakdown of the basement membrane during metastasis also drives tumor angiogenesis by increasing the availability of angiogenic growth factors such as vascular endothelial growth factor, and HS fragments which can drive FGF signaling [41] . Heparanase causes increased expression of these growth factors, as well as syndecan-1, which is shed from the cell surface at a higher rate. This shed syndecan-1 concentrates growth factors in the tumor microenvironment, accelerating proliferation and angiogenesis [42] .
In addition to its anticoagulant activity, heparin has been shown to have anti-inflammatory and anti-metastatic properties, primarily through binding L-selectin and P-selectin, which inhibit the ability of invading cells to bind to the endothelial surface [37, 43, 44] . Heparin has shown positive effects in acute inflammatory conditions such as bronchial asthma, ulcerative colitis and burns, and LMWH was found to afford a survival benefit (independent of its anticoagulant activity) to cancer patients [28, 37, [45] [46] [47] . However, complications associated with the anticoagulant properties of heparin may limit its use in these applications. Heparin and LMWH may have additional anti-cancer and anti-inflammatory effects due to its ability to competitively inhibit heparanase, but evidence remains scant. However, heparanase inhibiting heparin mimetics such as PI-88 and PG545, have shown potent anti-metastatic and antiangiogenic effects, and are currently in clinical trials [46, 48] .
A key element of the multifaceted biological activity of HS-GAGs is their complex structure and regulation. Detailed knowledge of structure-activity relationships will be essential for developing new therapeutics, which target HS-GAG associated processes. One major roadblock has been the inability to synthesize GAGs with defined structures. The complexity of HS largely precludes its chemical synthesis. However, new approaches, such as chemoenzymatic synthesis and bioengineering, offer promising results.
Preparation of unfractionated heparin and HS from animal sources
Methods
Methods of commercial production of pharmaceutical grade heparin are tightly guarded industrial secrets and few publications or patents describe most commonly used pharmaceutical processes. Large-scale 
The methods used today for the commercial preparation of heparin evolved from what was used early this century, with five basic steps: 1) preparation of tissues; 2) extraction of heparin from tissues; 3) recovery of raw heparin; 4) purification of heparin; and 5) purified heparin recovery (Fig. 4) [49, 50] . The preparation of the tissue begins with the collection of the appropriate animal organ tissue at the slaughterhouse and its preparation for processing. The whole intestine is either used to prepare "hashed pork guts" or processed into casings, which requires scraping of the endothelial lining from the intestinal lumen (mucosa). Hashed guts and mucosa are preserved with 0.5-3.5% sodium metabisulfite or another suitable oxygen scavenger to prevent spoilage. In the past, all of the hashed gut and mucosa were transferred to a heparin manufacturing facility for further processing as shown in Fig. 4. 
Issues and problems
In 2008 there was an unprecedented heparin crisis that markedly reduced the supply of heparin that could be used therapeutically. This crisis involved the introduction of an oversulfated chondroitin sulfate (OSCS) into heparin produced from pigs in China, leading to the death of nearly 100 Americans in 2008 [51, 52] . This kind of deliberate adulteration was very difficult to detect since the tissue supply chain for heparin in slaughterhouses lacks current good manufacturing processes (cGMP) oversight. More recently, the mixing of heparin obtained from different animal species has been suspected. Bovine lung heparin, ovine intestinal heparin and porcine intestinal heparin can be distinguished from one another by their different distribution of structural variants of the AT pentasaccharide binding site as well as differences in their disaccharide compositions [53, 54] . However, it is very difficult to detect the presence of small amounts of bovine intestinal heparin or ovine intestinal heparin in a porcine intestinal heparin product even using current state-of-theart level analytical methods [54, 55] . In fact, drug preparation from animal sources is always a concern. Pharmaceutical grade heparins and HS have been derived from a variety of animal tissues throughout heparin production history [2] . These animal source materials can contain infectious agents leading to the potential transmission of viral and prion diseases. Moreover, the susceptibility of animal populations to infectious disease, such as porcine epidemics in China, overharvesting, or environmental concerns can dramatically reduce the supply animals from which heparin can be prepared [56] . Additionally, product quality can vary with environmental factors and animal subspecies, providing additional difficulties for drug regulation. Serious concerns over prion diseases such as bovine spongiform encephalopathy (BSE, "mad cow disease"), which causes Creutzfeldt-Jakob disease in humans [57] , and the scrapies prion in sheep [58] have led to a decline in the use of bovine and ovine tissues as a source of heparin. However, with increasing spot shortages of heparin, the re-introduction of bovine heparin on the US market is under serious consideration to alleviate potential shortages in the supply of heparin and to decrease the risk of relying on a single species for this critical, lifesaving drug.
Unfortunately, despite the 1.2 billion or more pigs that are slaughtered each year worldwide, corresponding to N100 tons/year of heparin production, commercial suppliers may not be able to keep pace with increased worldwide demand particularly in developing countries. Recent market share analysis showed that the majority of crude heparin is sourced from China, which supplies about 57% of the worldwide market [59] . The potential shortage risk due to the single animal/single country sourcing of heparin has led to a push for the re-introduction of bovine heparin to bolster supply, despite concerns about potential mixing of porcine and bovine heparins and transmission of CJD. The development of non-animal sourced heparin and heparin-like drugs are urgently needed in the current market.
Chemical synthesis and depolymerization of heparin/HS and analogs
Chemical synthesis of Ultra LMWH
Numerous synthetic steps, low product yields, and high costs preclude the chemical syntheses of full-length heparin chains based on current Fig. 4 . Extractive preparation of heparin, HS and LMWHs. Typical process steps are shown the anion-exchange step is used in recovering GAG and the cation-exchange step is used in removing cationic impurities.
technology. However, it is possible to prepare ultra low molecular weight heparin (ULMWH) and LMWH by the chemical or enzymatic depolymerization of unfractionated heparins or through chemical synthesis. The idea of making a synthetic version of heparin is not new, in 2002 Sanofi introduced a synthetic heparin pentasaccharide, Arixtra® (fondaparinux sodium) [60] . This drug was based on a simplification of the elegant synthesis of the heparin AT pentasaccharide binding site, first reported by Choay and coworkers in the 1980s [61] . Arixtra® differs from heparin in that it is a specific anti-FXa agent, which lacks many of the pharmacological properties of the polycomponent, polypharmacolgical drug as heparin [62] , and its anticoagulant activity cannot be reversed using protamine, which is a basic protein administered to form a charge-neutral complex with heparin, neutralizing heparin's anti-clotting effects.
Chemical and enzymatic depolymerization of unfractionated heparin to prepare LMWHs
LMWHs are fractionated heparins with a molecular weight ranging from~3-8 kDa used as selective anti-FXa anticoagulant/antithrombotic agents [14] . The commercial preparation of LMWHs from animalsourced unfractionated heparin often relies on the controlled chemical depolymerization of heparin using reactions such as peroxidative cleavage, nitrous acid cleavage, and chemical β-elimination [63] .
Much milder enzymatic depolymerization, using heparin lyases isolated from Flavobacterium heparinum, has also been used to make LMWHs such as Tinzaparin. Heparin lyase I is most commonly used to enzymatically depolymerize heparin (Fig. 5) [15, [64] [65] [66] . Studies have demonstrated that heparin lyase I is highly selective for → 4)-α-DGlcNS3S6S(1 → 4)-α-L-IdoA2S(1→, a linkage present in the AT-binding site, while heparin lyase II is more selective for →4)-α-D-GlcNS6S(1 → 4)-4)-α-L-IdoA(1→ [67] [68] [69] . Thus, heparin lyase II may represent an alternative cleavage enzyme for LMWH preparation [70] . Compared with chemical approaches, the mild conditions favored by heparin lyases offers the advantage of producing LMWHs with fewer process artifacts generated through side reactions.
Issues and problems
The current worldwide heparin market is evenly split between the use of heparin and LMWHs, with very little synthetic ULMWH being used [59, 71] . Only~5% of the heparin market is comprised of the expensive synthetic ULMWH, fondaparinux, which is used primarily when side effects such as heparin-induced thrombocytopenia are anticipated. Demand for fondaparinux remains low due to its high cost, poorer pharmacological profile, irreversibility and ineffectiveness in a number of applications [59, 71] . A new synthetic ULMWH called semuloparin, which is prepared by a selective and controlled depolymerization of heparin through a β-elimination reaction, was recently developed for the prevention of venous thromboembolism [72] . The depolymerization leaves more AT-binding sites intact within longer chains. The anti-factor Xa/IIa ratio from clinical studies is N30, which indicates semuloparin is a selective anti-factor Xa agent [73] . Although the preparation cost is significantly lower than that of fondaparinux, it is neither homogeneous nor structurally defined, and since it is still derived from porcine intestinal heparin, semuloparin as well as other LMWHs, could be subject to contamination or adulteration.
LMWHs including enoxaparin, ardeparin sodium, dalteparin sodium, nadroparin calcium, reviparin sodium and certroparin sodium rely on harsh chemical depolymerization conditions resulting in process-derived artifacts, such as 2,6-anhydromannitol, epoxide, 1,6-anhydroglucopyranose, and 1,6-anhydromannopyranose [74] [75] [76] . The potential side effects associated with these process artifacts still remain unknown. Enzymatic depolymerization can circumvent some of these problems, although it is not without its own problems, such as AT binding site pentasaccharide protection and chain length control to avoid overdigestion. Without chain length control, overdigestion of heparin can convert an active LMWH into smaller disaccharides and tetrasaccharides, which lack bioactivity. Is it possible to control enzymatic depolymerization utilizing molecular weight cut-off membranes to control chain length [70] . However, further studies are required to access the in vivo biological activities and pharmacological efficacy of this kind of size refined LMWH.
Bioengineering ULMWH, LMWH and heparin
The chemoenzymatic synthesis of full-length heparin, HS, LMWH and ULMWH as investigational drugs has now become possible with the successful expression of recombinant heparin biosynthetic enzymes including glycosyltransferases and sulfotransferases (Table 1) [77] [78] [79] [80] . There are two types of processes used in chemoenzymatic synthesis. In the first, a single target structure, typically an ULMWH or a LMWH, is selected and an iterative chemoenzymatic scheme for its synthesis is designed and executed to afford a single molecular entity. In the second, the target is polycomponent heparin chains, typically a LMWH or heparin, the chemoenzymatic synthesis begins with a highly polydisperse (weight average molecular weight/number average molecular weight N 1) large polysaccharide precursor heparosan, consisting of repeating disaccharide units of GlcNAc and GlcA, then relies on chemical and/or enzymatic treatment to obtain a lower molecular weight and less polydisperse, microheterogenous product.
Iterative synthesis of defined targets
A fondaparinux-like ULMWH (Figs. 1 & 6) having comparable in vivo and in vitro anticoagulant activities was chemoenzymatically synthesized using heparin biosynthetic enzymes [80] . This approach mimics the heparin biosynthetic pathway, relying on recombinant synthases, C5-epimerase, 2OST, 6OSTs and 3OST enzymes, and afforded a homogeneous heptasaccharide in 12-steps, at multi-milligram scale, and iñ 40% overall yield. This ULMWH was synthesized from UDP-sugar donors (the natural UDP-GlcA, UDP-GlcNAc and the unnatural UDPGlcN-trifluoracetate (-GlcNTFA)) and a heparosan-derived disaccharide acceptor containing a ring-contracted anhydromannitol residue (Fig. 6) using N-acetyl glucosaminyltransferase (KfiA) and heparosan synthase (pmHS2) [81] . Enzyme catalyzed chain elongation provides the correct anomeric stereochemistry in over 80% percent yield, which would be impossible to achieve using chemical glycosylation. The resulting heptasaccharide was selectively epimerized with C5-epimerase and 2-O-sulfo groups were added using 2OST, converting GlcA into its sulfated C5-epimer IdoA2S. This selectivity requires the NST pre-treatment before C5-epimerase and 2OST [82] . C5-epimerase only converts GlcA residues between two GlcNS residues [82, 83] to IdoA and works best in conjunction with 2OST, which locks the normally reversible reaction into the IdoA epimer with the introduction of a 2-O-sulfo group [84] . Complete introduction of 6-O-sulfo groups relies on two of the three 6OST isoforms, 6OST-1 and 6OST-3, which transfer sulfo groups to GlcNS residues next to GlcA and IdoA2S residues, respectively [50] . The selective introduction of a single 3-O-sulfo group with 3OST-1 completed the ULMWH. Interestingly, there are at least 6 different 3OST isoforms with distinct substrate specificities. Two of these, 3OST-1 and 3OST-3 have been crystallized and their structures [85, 86] reveal different binding modes for the two isoforms, allowing recognition of distinct modification sites. 3OST-1 affords the AT-binding site and 3OST-3 affords an oligosaccharide that binds the gD envelope protein of herpes simplex virus 1 [32, 87] . While this approach appears straightforward and simple, it is the result of a carefully optimized synthetic design.
Starting from a commercially available p-nitrophenylglucuronide acceptor this iterative chemoenzymatic synthesis has been extended to the preparation of LMWHs, up to the size of dodecasaccharides [88] . In 22-steps, many fewer than required for the chemical synthesis of fondaparinux, this decasaccharide was obtained in~40% yield (Fig. 6 ). This homogenous LMWH showed only anti-factor Xa activity that could be completely reversed with protamine sulfate. Furthermore, it was cleared from the circulation through the liver, allowing the potential use of this agent in patients with renal impairment. Thus, iterative chemoenzymatic synthesis offers an effective approach to prepare the next generation of LMWHs with improved therapeutic properties.
Chemoenzymatic synthesis of polycomponent heparins
A chemoenzymatic alternative to heparin called "neoheparin" was first prepared in 2005 (Fig. 7) [89] . This approach began with Escherichia coli K5 as a source of the polysaccharide backbone, heparosan, which is then chemically de-N-acetylated and N-sulfonated. This Nsulfoheparosan was treated with recombinant C5-epimerase and then chemically per-O-sulfonated and selectively chemically O-desulfonated. Unfortunately, this neoheparin product contained unnatural sequences including 3-O-sulfo glucuronic acid (GlcA3S), not found in mammalian heparins. In light of the heparin contamination crisis involving a per-Osulfonated GAG oversulfated chondroitin sulfate (OSCS), also with unnatural GlcA3S sequences, the introduction of neoheparin poses real concerns.
A chemoenzymatic approach that more closely mimics the heparin biosynthetic pathway has been developed to produce "bioengineered heparin." This approach again relies on the E. coli K5 capsular polysaccharide (CPS), heparosan, as the starting material [90] . Chemical (or enzymatic) de-N-acetylation and N-sulfonation of heparosan affords Nsulfoheparosan that is subsequently modified using recombinantly expressed C5-epimerase and OSTs [91] (Fig. 6 ). This chemoenzymatic preparation of bioengineered heparin differs from neoheparin in that it relies on enzymatic modification of the N-sulfoheparosan chain affording a product that closely resembles the heparin natural product. Moreover, bioengineered heparin eliminates many undesirable structural artifacts present in the animal-derived heparins including linkage region sugars, bleach-modified and base-modified saccharides. The major challenge of making a bioengineered heparin is meeting the annual global demand of more than 100 tons per year [50, 51, 92, 93] .
The large-scale preparation of bioengineered heparin can be subdivided into upstream, midstream and downstream processes. The upstream fermentation of E. coli has been optimized to obtain high yields of heparosan CPS [94, 95] . Metabolic engineering approaches may offer further improvements in the yield of heparosan [96] . A recombinant E. coli BL21 strain, which produces nearly 2 g/L of heparosan, was prepared by introducing four heparosan biosynthetic genes (KfiA-D) from E. coli K5 [97] . The production of the structurally related chondroitin CPS from glucose using an engineered E. coli was also recently reported [98] . Control of the molecular weight of the heparosan CPS obtained from E. coli K5 may also be required [99, 100] . Beside manipulation of culture conditions, chain termination and genetic optimization also can be possible to control the molecular weight of heparosan [101] . Infection with phage carrying heparosan lyase has also been examined as a means to control molecular weight [102] . The midstream process involves the conversion of heparosan to N-sulfoheparosan. Base-catalyzed N-deacetylation can be carefully controlled using a response surface algorithm that gives the proper content of residual Nacetyl groups and the correct molecular weight properties [99] . The downstream process involves treating N-sulfoheparosan with recombinant C5-epimerase and OSTs in the presence of the cofactor 3′-phosphoadenosine-5′-phosphosulfate (PAPS). A cofactor recycling system, involving arylsulfotransferase-IV (AST-IV), is used to convert spent, expensive cofactor 3′-phosphoadenosine-5′-phosphate (PAP) to PAPS by transferring a sulfo group from an inexpensive sacrificial donor, p-nitrophenyl sulfate (PNPS), to PAP, regenerating PAPS. The reaction also produces p-nitrophenol (PNP) that can be recovered and chemically sulfonated. This cofactor regeneration system saves on cost, since PAPS is nearly 1000-fold more expensive than PNPS. Coupling this reaction to OST reactions not only overcomes strong product inhibition of these sulfotransferases by PAP [103] , but also provides a reaction monitoring system. PNP produced by the reaction absorbs light at 400 nm wavelengths, which forms the basis of our current colorimetric sulfotransferase assay [104, 105] .
Careful design of the reaction scheme and process control is necessary to prepare a bioengineered heparin that is chemically and biologically equivalent to currently used animal-derived heparin. Other key challenges for future commercialization include scale-up, reduction in the costs of heparosan, PAPs and recombinant enzymes [103, [106] [107] [108] [109] .
Recently, a one-pot chemoenzymatic synthesis of complex fulllength heparin/HS polysaccharides was described [110] . This one-pot approach begins with the substrate N-sulfoheparosan that is simultaneously treated with C5-epimerase and 2-OST with and low levels of 6-OST, followed by 3-OST. By optimizing the enzyme/substrate ratio the structure of the final bioengineered heparin can be controlled. It is possible that such an optimized, simplified process can one day be applied to facilitate the large-scale production of a bioengineered heparin.
Metabolic engineering
While the field of metabolic engineering is still in its infancy, some steps toward the metabolic engineering of HS-GAGs have been made. One strategy has been to alter the natural HS produced by Chinese hamster ovary cells into a more heparin-like product. CHO cells have a number of advantages over other metabolic engineering systems, including the natural glycosylation of CHO cell proteins, and a proven use in producing therapeutic glycoproteins [111] . Transfecting CHO cells with human genes encoding for NDST-2 and 3OST-1 (NDST2 and Hs3st1 respectively) produced an HS with increased AT-binding and anticoagulant activity, although the disaccharide composition of this HS varied significantly from pharmaceutical heparin [112] . With a much higher percentage of GlcA-GlcNS disaccharides, the expression level of NDST-2 outpaced the native OSTs, 2-OST and 6-OST, whose modifications may be required for the action of 3OST-1. Further improvement of anticoagulant activity was reported by targeting 3OST-1 expression to the Golgi, which may also upregulate native OSTs [113] . Mass spectroscopy analysis of this CHO cell HS was able to confirm the presence of the AT binding site. However, CHO cell engineering of a heparin-like product will require better pathway control, including the upregulation of critical 2-OST and 6-OST enzymes. CRISPR/CAS9 offers an approach to control the expression of multiple enzymes within the heparin biosynthetic pathway [96] . Even if CHO cell expression of heparin were achieved by a method such as CRISPR/CAS9, the scale of production would probably never exceed 10-100 kg/y, well below the 100-ton scale needed to replace animal-derived heparin.
An alternate strategy to prepare commercial quantities of heparin is to metabolically engineer bacteria. The pathway of CPS biosynthesis and secretion from E. coli is well established [90] . Moreover, the expression levels of enzymes in this pathway have been successfully controlled using CRISPR/CAS9 [96] . E. coli is able to express active recombinant forms of many of the heparin biosynthetic enzymes, including C5-epimerase and all types of OSTs [50] . Finally, E. coli is known to biosynthesize PAPS [114] . Thus, if the remained of the heparin biosynthetic enzymes could be actively expressed, made to act in an organized fashion and heparin could be secreted like a CPS, it is possible to envision the large-scale preparation of a metabolically engineered microbial heparin.
Conclusions and future prospects
Homogenous ULMWHs and LMWHs have been chemoenzymatically synthesized in multi-milligram quantities and their activities have been evaluated both in vitro and in vivo [80, 88] . These agents offer some chemical and pharmacological advantages over the currently approved ULMWHs and LMWHs [88] . Preclinical evaluation of these chemoenzymatically synthesized ULMWHs and LMWHs in multiple animal species will be needed if these are to be approved for human use. The major driving force for such an approval will be their improvements over the currently approved ULMWHs and LMWHs. Some improvements might include: more defined or improved pharmacokinetics/ pharmacodynamics associated with their homogenous structures [88] ; their ability to be neutralized with protamine sulfate [88] ; improved clearance through the liver allowing their use in renal compromised patients [88] ; reduced side-effects such as bleeding and heparin-induced thrombocytopenia (HIT). The small-scale chemoenzymatic synthesis of bioengineered heparin has been successful accomplished and is ongoing to scale-up for pre-clinical evaluation. Additional effort will be required to improve both the bioengineered heparin process and the quality of the final product. Metabolically engineered CHO cells might be useful for producing high-value "designer heparins" with special properties allowing their high-cost, small-scale production. Metabolic engineering of prokaryotes (without a Golgi), such as E. coli, posses even greater challenges [96, 107] . While the metabolic engineering of a single strain of engineered bacteria to produce heparin is far off, there are a number of intermediate steps that could be introduced sooner using a biotransformation approach. It is possible to envision several engineered bacteria each producing a component of a bioengineered heparin, for example, PAPS, heparosan and biosynthetic enzymes. These might then used in co-culture to effectively produce commercial quantities of a low cost bioengineered heparin.
Heparin, an anticoagulant drug, is one of the few GAGs that commands a multi-billion dollar market [59] . Thus, it is not surprising that all the initial investigation in chemoenzymatic synthesis and bioengineering approaches have focused on heparin and its derivatives. As HS and HS oligosaccharides become interesting therapeutic agents or are incorporated into biomaterials, the same approaches used for heparin should be directly translatable to HS. The future is bright for the controlled use of recombinant enzymes and metabolically engineered cells in the synthesis of HS, heparin and their derivatives.
